Project Details
Description
A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second-or Third-line Treatment of Subjects with Unresectable or Peritoneal Malignant Mesothelioma
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/13 → 6/30/18 |
Funding
- MEDIMMUNE, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.